Stockscreener 앱 받기
40.65
18.62%
-9.30
시간 외 거래:
40.99
0.34
+0.84%
전일 마감가:
$49.95
열려 있는:
$39.44
하루 거래량:
4.20M
Relative Volume:
4.43
시가총액:
$3.80B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-6.8434
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
-18.31%
1개월 성능:
-5.99%
6개월 성능:
-0.54%
1년 성능:
+23.14%
1일 변동 폭
$38.76
$42.12
1주일 범위
$38.76
$50.43
52주 변동 폭
$28.72
$58.38
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
40.65 | 3.80B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Benzinga
Leerink maintains $52 target on PTC Therapeutics stock By Investing.com - Investing.com India
Leerink maintains $52 target on PTC Therapeutics stock - Investing.com
PTC's Novartis-partnered Huntington's drug disappoints in mid-stage data reveal - FirstWord Pharma
PTC’s Huntington’s study succeeds, but accelerated approval uncertain - Endpoints News
PTC Therapeutics stock drops after Huntington’s study update - Investing.com Australia
PTC Therapeutics price target lowered to $57 from $65 at RBC Capital - TipRanks
RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating - marketscreener.com
PTC Therapeutics (PTCT) Announces Stock Option Grants for New Employees - GuruFocus
PTC Therapeutics (PTCT) Faces Scrutiny Over Phase 2 Study Data | PTCT Stock News - GuruFocus
Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result - GuruFocus
PTC Therapeutics Reports Positive Phase 2 Study Results - TipRanks
PTC stock slides on new data for Huntington’s drug - Yahoo Finance
PTC518 shows promise in Huntington’s disease trial By Investing.com - Investing.com Canada
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint - marketscreener.com
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics (PTCT) Announces Promising Phase 2 Results for Huntington's Treatment | PTCT Stock News - GuruFocus
PTC518 PIVOT-HD Study Achieves Primary Endpoint | PTCT Stock News - GuruFocus
PTC518 shows promise in Huntington’s disease trial - Investing.com Australia
PTC518 PIVOT-HD Study Achieves Primary Endpoint - Quantisnow
Schonfeld Strategic Advisors LLC Sells 66,953 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nebula Research & Development LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by PDT Partners LLC - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by First Trust Advisors LP - MarketBeat
Raymond James Financial Inc. Purchases Shares of 48,728 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Price T Rowe Associates Inc. MD Trims Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Teachers Retirement System of The State of Kentucky Takes $940,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Aquatic Capital Management LLC - MarketBeat
Susquehanna Fundamental Investments LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
What is Leerink Partnrs' Forecast for PTCT FY2026 Earnings? - MarketBeat
Adage Capital Partners GP L.L.C. Increases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Tower Research Capital LLC TRC Buys 16,110 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PTCT Stock News - GuruFocus
Invesco Ltd. Purchases 57,582 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Canada Pension Plan Investment Board Buys New Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Wells Fargo & Company MN - MarketBeat
Guggenheim Capital LLC Has $880,000 Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance
PTC Therapeutics: Strategic Advancements and Market Opportunities Drive Buy Rating - TipRanks
PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - MSN
PTC Therapeutics (NASDAQ:PTCT) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
PTC Therapeutics (PTCT) Gains EMA Support for Phenylketonuria Dr - GuruFocus
Short Interest in PTC Therapeutics, Inc. (NASDAQ:PTCT) Increases By 26.0% - MarketBeat
PTC Therapeutics (PTCT) Advances Sephience for Phenylketonuria i - GuruFocus
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):